Minimally Invasive Devices, a developer of FloShield laparoscopic vision system that prevents loss of vision during laparoscopic surgery due to obscuration of the optics, has secured $9m from Series B financing.
The company said Canaan Partners has led the financing and its existing investor Charter Life Science has participated in the round.
The capital will be used by the company to establish a direct sales force, expand manufacturing operations, develop complimentary products and generate additional data to support the efficacy of the FDA-approved FloShield system.
Minimally Invasive Devices founder and CEO Wayne Poll said, "Obscuration of images due to contaminants on the optics is a real problem that surgeons have long taken for granted."
Canaan Partners general partner Brent Ahrens said, "FloShield is an elegant solution to this very real problem and has the potential to be expanded to other endoscopy platforms."
FloShield system, which is attached to the HD camera system and uses an air curtain to form an invisible protective barrier over the lens, is augmented by the Flo-X lens wash that flushes the lens inside the body if needed and enables surgeons to perform the surgery without loss of vision and without lens removal.
